13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001017645
Total reported value
$2.9B
$2.9B
13 檔
72.3%
At the close of Q4 2025, General Atlantic, L.p. disclosed equity holdings valued at approximately $2.9B, spread across 13 reported holdings.
In Q4 2025, General Atlantic, L.p. adopted a defensive or profit-taking posture, trimming 4 positions and completely liquidating 4 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including DLO, CHYM, XPEV) accounted for 72.3% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DLO | DLocal Limited | Stock-Other | 22.97% | -7.31% | — | |
| 2 | CHYM | Chime Financial Inc-cl A | Stock-Other | 18.63% | -3.55% | +10.68% | |
| 3 | XPEV | XPeng Inc. | Stock-Other | 12.93% | -6.73% | -11.05% | |
| 4 | ALKT | Alkami Technology Inc | Stock-Other | 9.63% | +0.89% | — | |
| 5 | ALHC | Alignment Healthcare Inc | Stock-Other | 9.05% | — | -45.78% | |
| 6 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 7.80% | -0.89% | +13.68% | |
| 7 | PHVS | Pharvaris N.V. | Stock-Other | 7.76% | -2.77% | — | |
| 8 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 5.33% | -2.50% | EXIT | |
| 9 | NRIX | Nurix Therapeutics Inc | Stock-Other | 3.23% | -0.43% | — | |
| 10 | EWCZ | European Wax Center Inc-a | Stock-Other | 1.64% | -3.53% | EXIT | |
| 11 | RSKD | Riskified Ltd. | Stock-Other | 0.92% | -0.05% | — | |
| 12 | GROV | Grove Collaborative Holdings | Stock-Other | 0.09% | -0.04% | — | |
| 13 | ✓ | Stock-Other | 0.01% | -0.01% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CHYM | Chime Financial Inc-cl A | +7% | +10.68% | Add |
| 2 | RVMD | Revolution Medicines Inc | +4.3% | +13.68% | Add |
| 3 | DLO | DLocal Limited | +3% | — | Unchanged |
| 4 | PHVS | Pharvaris N.V. | +1.7% | — | Unchanged |
| 5 | ALKT | Alkami Technology Inc | +0.7% | — | Unchanged |
| 6 | RSKD | Riskified Ltd. | +0.2% | — | Unchanged |
| 7 | EWCZ | European Wax Center Inc-a | +0.1% | — | Unchanged |
| 8 | GROV | Grove Collaborative Holdings | 0% | — | Unchanged |
| 9 | XPEV | XPeng Inc. | -1.5% | -11.05% | Trim |
| 10 | 260 | Centessa Pharmaceuticals-adr | -1.7% | -36.81% | Trim |
| 11 | ✓ | -3.2% | -99.29% | Trim | |
| 12 | ALHC | Alignment Healthcare Inc | -3.7% | -45.78% | Trim |
| 13 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 14 | NRIX | Nurix Therapeutics Inc | — | NEW | New buy |
| 15 | RPRX | Royalty Pharma plc | — | EXIT | Sold out |
| 16 | ADAG | Adagene Inc-adr | — | EXIT | Sold out |
| 17 | ALMS | Alumis Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, General Atlantic, L.p. reported a total U.S. public equity portfolio value of $2.9B across 13 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
NRIX
市值: $92.9M
Top Position Liquidated / Trimmed
AKRO
前期市值: $272.2M
During Q4 2025, General Atlantic, L.p.'s top holdings by market value included DLO (23.0%)、CHYM (18.6%)、XPEV (12.9%). The largest single position, DLO, represented 23.0% of total portfolio value.
In Q4 2025, General Atlantic, L.p. made 11 total portfolio adjustments, initiating 1 new buys, adding to 2 positions, trimming 4 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.